C
NBIX icon

Covestor’s Neurocrine Biosciences NBIX Stock Holding History

Covestor’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62K Sell
467
-261
-36% -$34.6K 0.04% 571
2025
Q4 		$103K Sell
728
-175
-19% -$25.4K 0.05% 562
2025
Q3 		$127K Sell
903
-691
-43% -$93.6K 0.07% 438
2025
Q2 		$200K Sell
1,594
-158
-9% -$18.1K 0.12% 189
2025
Q1 		$194K Sell
1,752
-259
-13% -$32.8K 0.13% 169
2024
Q4 		$275K Buy
2,011
+232
+13% +$28.7K 0.17% 76
2024
Q3 		$205K Buy
1,779
+183
+11% +$25.1K 0.13% 159
2024
Q2 		$220K Sell
1,596
-148
-8% -$20.3K 0.14% 141
2024
Q1 		$241K Buy
1,744
+136
+8% +$18.6K 0.15% 104
2023
Q4 		$212K Buy
1,608
+814
+103% +$93.7K 0.14% 117
2023
Q3 		$89K Sell
794
-852
-52% -$89.7K 0.07% 488
2023
Q2 		$155K Buy
1,646
+895
+119% +$87.4K 0.12% 220
2023
Q1 		$76K Buy
751
+520
+225% +$54.1K 0.07% 530
2022
Q4 		$28K Buy
231
+108
+88% +$12.7K 0.02% 937
2022
Q3 		$13K Hold
123
– – 0.01% 1158
2022
Q2 		$12K Sell
123
-254
-67% -$23.4K 0.01% 1147
2022
Q1 		$35K Buy
377
+306
+431% +$25.9K 0.02% 914
2021
Q4 		$6K Buy
+71
New +$6.53K 0.01% 1238

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Covestor's NBIX Position: Q1 2026 in Review

Covestor reduced its Neurocrine Biosciences (NBIX) stake by 36% in Q1 2026, selling an estimated $34.6K and leaving 467 shares worth $62K. The position accounts for 0.04% of the portfolio, ranked #571.

Covestor first reported a position in NBIX in Q4 2021 and has held it in 18 quarters since. The position peaked at $275K in Q4 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Covestor held 467 shares of Neurocrine Biosciences worth $62K as of Q1 2026.
  • Covestor sold 261 Neurocrine Biosciences shares in Q1 2026, an estimated $34.6K.
  • Neurocrine Biosciences made up 0.04% of Covestor's portfolio in Q1 2026, its #571 holding.
  • Covestor first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 18 quarters since.
  • Covestor's Neurocrine Biosciences position peaked at $275K in Q4 2024.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.